Reading: Pancreatic Cancer Drug Daraxonrasib Shows Rare Response in Trial

Pancreatic Cancer Drug Daraxonrasib Shows Rare Response in Trial

Published
3 min read
Advertisement

A pancreatic cancer drug called daraxonrasib made tumours undetectable on CT scans in about 8% of patients in a trial of 61 people with advanced disease that had already spread. Dr Wungki Park said he had never seen so many tumours disappear in patients whose cancer had metastasised.

The findings, presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, are being read as one of the clearest signs yet that a KRAS inhibitor can drive deep responses in a disease long treated as almost untouchable. The patients were followed for an average of 18 months, and 76.6% were alive a year after starting treatment.

That matters because pancreatic cancer that has spread to other organs usually moves fast. Half of all people diagnosed with the disease die within three months, and only about 3% survive for five years once it reaches other organs. In that setting, seeing tumours stop growing in 90% of patients and shrink or disappear in just over 60% is a result that immediately stands out.

- Advertisement -

Daraxonrasib works by locking on to and shutting off certain KRAS mutations found in most pancreatic cancers, mutations that drive tumour growth. Researchers also said the treatment could potentially work for dozens of other cancers because similar mutations appear there too. Michelle Mitchell called the result the biggest leap forward seen in decades for pancreatic cancer patients and said it could eventually open the door to treating other cancers with KRAS mutations.

Even so, the pill is not being treated as a cure. Doctors said they do not yet know how long it can keep the disease at bay, and Mitchell said more trials are needed before it can be assessed for use on the NHS. Park was even more direct, saying the closest thing to a cure was visible in the scan results, but not yet proved in the long run.

The unanswered question is not whether daraxonrasib can hit its target. It already has. What still has to be shown is how long those responses last, and whether a drug that can make advanced pancreatic cancer disappear on scans can keep it away for long enough to change the disease for good.

Advertisement
Share This Article